drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00041 | DB00312 | 1,648 | 1,023 | [
"DDInter38",
"DDInter1423"
] | Aldesleukin | Pentobarbital | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Dr... | Moderate | 1 | [
[
[
1648,
24,
1023
]
],
[
[
1648,
24,
682
],
[
682,
40,
1023
]
],
[
[
1648,
24,
1042
],
[
1042,
63,
1023
]
],
[
[
1648,
25,
593
],
[
593,
... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentobarbital"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiopental"
],
... | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Thiopental and Thiopental (Compound) resembles Pentobarbital (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide and Tetracosactide may cause a moderate interacti... |
DB00814 | DB01099 | 1,171 | 1,272 | [
"DDInter1143",
"DDInter744"
] | Meloxicam | Flucytosine | Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve various types of pain, including pain caused by musculoskeletal conditions, osteoarthritis, and rheumatoid arthritis. With a longer half-life than most other NSAIDS, it is a favorable option for those who require once-daily dosing. Meloxicam is ... | A fluorinated cytosine analog that is used as an antifungal agent. | Moderate | 1 | [
[
[
1171,
24,
1272
]
],
[
[
1171,
21,
29164
],
[
29164,
60,
1272
]
],
[
[
1171,
24,
1448
],
[
1448,
24,
1272
]
],
[
[
1171,
63,
50
],
[
50... | [
[
[
"Meloxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flucytosine"
]
],
[
[
"Meloxicam",
"{u} (Compound) causes {v} (Side Effect)",
"Photosensitivity"
],
[
"Photosensitivity",
"{u} (Side Ef... | Meloxicam (Compound) causes Photosensitivity (Side Effect) and Photosensitivity (Side Effect) is caused by Flucytosine (Compound)
Meloxicam may cause a moderate interaction that could exacerbate diseases when taken with Streptomycin and Streptomycin may cause a moderate interaction that could exacerbate diseases when t... |
DB01244 | DB09038 | 762 | 1,450 | [
"DDInter192",
"DDInter636"
] | Bepridil | Empagliflozin | A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. It is no longer marketed in the United St... | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Moderate | 1 | [
[
[
762,
24,
1450
]
],
[
[
762,
64,
485
],
[
485,
24,
1450
]
],
[
[
762,
24,
659
],
[
659,
63,
1450
]
],
[
[
762,
63,
1061
],
[
1061,
... | [
[
[
"Bepridil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Bepridil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pentamidine"
],
[
"Pentamidin... | Bepridil may lead to a major life threatening interaction when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Bepridil may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause... |
DB00813 | DB06282 | 704 | 516 | [
"DDInter722",
"DDInter1053"
] | Fentanyl | Levocetirizine | Fentanyl, a potent opioid agonist, was developed in the 1950s to fill a need for strong and rapid analgesia. Because of these characteristics, fentanyl is commonly used to treat chronic cancer pain or in anesthesia.[Label,L6598,L6601,L6604,L6607,L922,L6610,L6613] Fentanyl is related to other opioids like [morphine] and... | Levocetirizine is a selective histamine H<sub>1</sub> antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine]. Levocetirizine has greater affinity for the histamine H<sub>1</sub> receptor than cetirizine. Levocetirizine was granted FDA approval in 1995. | Moderate | 1 | [
[
[
704,
24,
516
]
],
[
[
704,
63,
701
],
[
701,
24,
516
]
],
[
[
704,
40,
1454
],
[
1454,
24,
516
]
],
[
[
704,
24,
407
],
[
407,
6... | [
[
[
"Fentanyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Fentanyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
... | Fentanyl may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Fentanyl (Compound) resembles Sufentanil (Compound) and Sufentanil may cause a moderate interaction that could... |
DB00204 | DB01268 | 228 | 1,151 | [
"DDInter580",
"DDInter1731"
] | Dofetilide | Sunitinib | Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter. | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Major | 2 | [
[
[
228,
25,
1151
]
],
[
[
228,
6,
3958
],
[
3958,
45,
1151
]
],
[
[
228,
21,
28653
],
[
28653,
60,
1151
]
],
[
[
228,
23,
112
],
[
112,
... | [
[
[
"Dofetilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sunitinib"
]
],
[
[
"Dofetilide",
"{u} (Compound) binds {v} (Gene)",
"KCNH2"
],
[
"KCNH2",
"{u} (Gene) is bound by {v} (Compound)",
"Sunitinib"... | Dofetilide (Compound) binds KCNH2 (Gene) and KCNH2 (Gene) is bound by Sunitinib (Compound)
Dofetilide (Compound) causes Bradycardia (Side Effect) and Bradycardia (Side Effect) is caused by Sunitinib (Compound)
Dofetilide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Met... |
DB00655 | DB01278 | 559 | 1,021 | [
"DDInter682",
"DDInter1506"
] | Estrone | Pramlintide | Estrone, one of the major mammalian estrogens, is an aromatized C18 steroid with a 3-hydroxyl group and a 17-ketone. It is produced in vivo from androstenedione or from testosterone via estradiol. It is produced primarily in the ovaries, placenta, and in peripheral tissues (especially adipose tissue) through conversion... | Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes. | Moderate | 1 | [
[
[
559,
24,
1021
]
],
[
[
559,
1,
380
],
[
380,
24,
1021
]
],
[
[
559,
24,
708
],
[
708,
63,
1021
]
],
[
[
559,
1,
35
],
[
35,
63,
... | [
[
[
"Estrone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
]
],
[
[
"Estrone",
"{u} (Compound) resembles {v} (Compound)",
"Conjugated estrogens"
],
[
"Conjugated estrogens",
"{u} may ... | Estrone (Compound) resembles Conjugated estrogens (Compound) and Conjugated estrogens may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Estrone may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin and Corticotropin may cause a moderate i... |
DB04908 | DB06589 | 1,671 | 1,250 | [
"DDInter741",
"DDInter1400"
] | Flibanserin | Pazopanib | Flibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder... | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Moderate | 1 | [
[
[
1671,
24,
1250
]
],
[
[
1671,
23,
1135
],
[
1135,
62,
1250
]
],
[
[
1671,
64,
1419
],
[
1419,
24,
1250
]
],
[
[
1671,
24,
214
],
[
214... | [
[
[
"Flibanserin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Flibanserin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
... | Flibanserin may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Pazopanib
Flibanserin may lead to a major life threatening interaction when taken with Imatinib and Imatinib may cause a moderat... |
DB00691 | DB09054 | 1,058 | 384 | [
"DDInter1237",
"DDInter905"
] | Moexipril | Idelalisib | Moexipril is a non-sulfhydryl containing precursor of the active angiotensin-converting enzyme (ACE) inhibitor moexiprilat. It is used to treat high blood pressure (hypertension). It works by relaxing blood vessels, causing them to widen. Lowering high blood pressure helps prevent strokes, heart attacks and kidney prob... | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
1058,
24,
384
]
],
[
[
1058,
1,
479
],
[
479,
23,
384
]
],
[
[
1058,
63,
305
],
[
305,
24,
384
]
],
[
[
1058,
24,
891
],
[
891,
... | [
[
[
"Moexipril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Moexipril",
"{u} (Compound) resembles {v} (Compound)",
"Donepezil"
],
[
"Donepezil",
"{u} may cause a minor inter... | Moexipril (Compound) resembles Donepezil (Compound) and Donepezil may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Moexipril may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a... |
DB00030 | DB00524 | 1,685 | 811 | [
"DDInter934",
"DDInter1199"
] | Insulin human | Metolazone | Human Insulin, also known as Regular Insulin, is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mel... | A quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic renal failure. It also tends to lower blood pressure and increase potassium loss. | Moderate | 1 | [
[
[
1685,
24,
811
]
],
[
[
1685,
24,
1605
],
[
1605,
40,
811
]
],
[
[
1685,
24,
964
],
[
964,
23,
811
]
],
[
[
1685,
24,
1620
],
[
1620,
... | [
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metolazone"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indapamide"
],
... | Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Indapamide and Indapamide (Compound) resembles Metolazone (Compound)
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Doxycycline and Doxycycline may cause a minor interaction that ... |
DB00314 | DB00994 | 894 | 361 | [
"DDInter288",
"DDInter1277"
] | Capreomycin | Neomycin | Cyclic peptide antibiotic similar to viomycin. It is produced by Streptomyces capreolus. | Neomycin is a broad-spectrum aminoglycoside antibiotic drug that is derived from the metabolic products of _Streptomyces fradiae_. Neomycin is a complex comprised of three components, neomycin A, B, and C. Neomycin B, also known as [framycetin], is the most active component of the complex and neomycin C is the isomer o... | Major | 2 | [
[
[
894,
25,
361
]
],
[
[
894,
21,
29357
],
[
29357,
60,
361
]
],
[
[
894,
25,
1132
],
[
1132,
24,
361
]
],
[
[
894,
24,
101
],
[
101,
... | [
[
[
"Capreomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neomycin"
]
],
[
[
"Capreomycin",
"{u} (Compound) causes {v} (Side Effect)",
"Nephropathy toxic"
],
[
"Nephropathy toxic",
"{u} (Side Effect) is cau... | Capreomycin (Compound) causes Nephropathy toxic (Side Effect) and Nephropathy toxic (Side Effect) is caused by Neomycin (Compound)
Capreomycin may lead to a major life threatening interaction when taken with Gentamicin and Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Neomyc... |
DB00224 | DB08870 | 215 | 850 | [
"DDInter917",
"DDInter228"
] | Indinavir | Brentuximab vedotin | A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem] | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Moderate | 1 | [
[
[
215,
24,
850
]
],
[
[
215,
24,
1142
],
[
1142,
24,
850
]
],
[
[
215,
25,
134
],
[
134,
24,
850
]
],
[
[
215,
63,
245
],
[
245,
2... | [
[
[
"Indinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Indinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orlistat"
],
... | Indinavir may cause a moderate interaction that could exacerbate diseases when taken with Orlistat and Orlistat may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Indinavir may lead to a major life threatening interaction when taken with Vinorelbine and Vinorelbine may c... |
DB00465 | DB09054 | 886 | 384 | [
"DDInter1010",
"DDInter905"
] | Ketorolac | Idelalisib | Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and is commercially available as an oral tablet, injectable, nasal spray and as an ophthalmic solution. It's analgesic properties make it a useful pain management tool across many settings including postoperative pain, rheumatoid arthritis, osteoarthritis, men... | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
886,
24,
384
]
],
[
[
886,
24,
222
],
[
222,
23,
384
]
],
[
[
886,
25,
1618
],
[
1618,
24,
384
]
],
[
[
886,
63,
305
],
[
305,
2... | [
[
[
"Ketorolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Ketorolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
... | Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Ketorolac may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may caus... |
DB00307 | DB09043 | 1,101 | 135 | [
"DDInter202",
"DDInter36"
] | Bexarotene | Albiglutide | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on A... | Major | 2 | [
[
[
1101,
25,
135
]
],
[
[
1101,
24,
467
],
[
467,
23,
135
]
],
[
[
1101,
62,
362
],
[
362,
24,
135
]
],
[
[
1101,
24,
870
],
[
870,
... | [
[
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Albiglutide"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
],
[
"Simvasta... | Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Bexarotene may cause a minor interaction that can limit clinical effects when taken with Phenytoin and Phenytoi... |
DB00581 | DB00582 | 355 | 1,622 | [
"DDInter1018",
"DDInter1946"
] | Lactulose | Voriconazole | Lactulose is a synthetic disaccharide derivative of lactose that is most commonly used as a laxative agent despite also being formally indicated to serve as an adjunct therapy in treating portal-systemic encephalopathy (PSE).[FDA Label,L6199,L6202] Despite being first synthesized in 1929, investigations regarding its p... | Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increase... | Moderate | 1 | [
[
[
355,
24,
1622
]
],
[
[
355,
21,
28785
],
[
28785,
60,
1622
]
],
[
[
355,
24,
823
],
[
823,
63,
1622
]
],
[
[
355,
63,
251
],
[
251,
... | [
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voriconazole"
]
],
[
[
"Lactulose",
"{u} (Compound) causes {v} (Side Effect)",
"Muscle spasms"
],
[
"Muscle spasms",
"{u} (Side Effect)... | Lactulose (Compound) causes Muscle spasms (Side Effect) and Muscle spasms (Side Effect) is caused by Voriconazole (Compound)
Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole and Triclabendazole may cause a moderate interaction that could exacerbate diseases when ... |
DB00022 | DB00060 | 268 | 912 | [
"DDInter1408",
"DDInter947"
] | Peginterferon alfa-2b | Interferon beta-1a | Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. | Moderate | 1 | [
[
[
268,
24,
912
]
],
[
[
268,
24,
1439
],
[
1439,
63,
912
]
],
[
[
268,
25,
876
],
[
876,
63,
912
]
],
[
[
268,
24,
305
],
[
305,
2... | [
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon beta-1a"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab and Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a
Peginterferon alfa-2b may lead to a major life threatening interaction when taken with Tizani... |
DB01005 | DB01044 | 995 | 246 | [
"DDInter894",
"DDInter809"
] | Hydroxyurea | Gatifloxacin | Hydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928. It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. Although clinical evidence on the efficacy of hydroxyurea in certain conditions exists, h... | Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatiflox... | Minor | 0 | [
[
[
995,
23,
246
]
],
[
[
995,
62,
739
],
[
739,
1,
246
]
],
[
[
995,
23,
945
],
[
945,
40,
246
]
],
[
[
995,
62,
1467
],
[
1467,
40... | [
[
[
"Hydroxyurea",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gatifloxacin"
]
],
[
[
"Hydroxyurea",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lomefloxacin"
],
[
... | Hydroxyurea may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Gatifloxacin (Compound)
Hydroxyurea may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Gatifloxacin (... |
DB00635 | DB01400 | 1,573 | 1,372 | [
"DDInter1515",
"DDInter1279"
] | Prednisone | Neostigmine | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike physostigmine, does not cross the blood-brain barrier. | Moderate | 1 | [
[
[
1573,
24,
1372
]
],
[
[
1573,
63,
751
],
[
751,
40,
1372
]
],
[
[
1573,
24,
61
],
[
61,
24,
1372
]
],
[
[
1573,
6,
4973
],
[
4973,
... | [
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neostigmine"
]
],
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pyridostigmine"
],
... | Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Pyridostigmine and Pyridostigmine (Compound) resembles Neostigmine (Compound)
Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Edrophonium and Edrophonium may cause a moderate interaction... |
DB00938 | DB09078 | 455 | 1,228 | [
"DDInter1635",
"DDInter1036"
] | Salmeterol | Lenvatinib | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progressi... | Moderate | 1 | [
[
[
455,
24,
1228
]
],
[
[
455,
63,
1100
],
[
1100,
24,
1228
]
],
[
[
455,
24,
938
],
[
938,
63,
1228
]
],
[
[
455,
25,
609
],
[
609,
... | [
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venlafaxine"
],
[
... | Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine and Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant and Pito... |
DB01359 | DB13142 | 729 | 841 | [
"DDInter1417",
"DDInter274"
] | Penbutolol | Calcium glubionate anhydrous | Penbutolol is a drug in the beta-blocker class used to treat hypertension. Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker. Penbutolol can act as a partial agonist at beta adrenergic receptors, since it is a sympathomimetric drug. Penbutolol also demonstrates high... | Calcium glubionate (or glubionate calcium) is a mineral supplement to prevent or treat low blood calcium levels in people who do not get enough calcium from their diets. | Moderate | 1 | [
[
[
729,
24,
841
]
],
[
[
729,
40,
461
],
[
461,
24,
841
]
],
[
[
729,
62,
1152
],
[
1152,
24,
841
]
],
[
[
729,
1,
699
],
[
699,
24... | [
[
[
"Penbutolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium glubionate anhydrous"
]
],
[
[
"Penbutolol",
"{u} (Compound) resembles {v} (Compound)",
"Timolol"
],
[
"Timolol",
"{u} may cau... | Penbutolol (Compound) resembles Timolol (Compound) and Timolol may cause a moderate interaction that could exacerbate diseases when taken with Calcium glubionate anhydrous
Penbutolol may cause a minor interaction that can limit clinical effects when taken with Liothyronine and Liothyronine may cause a moderate interact... |
DB00726 | DB01001 | 1,164 | 688 | [
"DDInter1876",
"DDInter1632"
] | Trimipramine | Salbutamol | Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Moderate | 1 | [
[
[
1164,
24,
688
]
],
[
[
1164,
64,
874
],
[
874,
24,
688
]
],
[
[
1164,
24,
455
],
[
455,
24,
688
]
],
[
[
1164,
24,
1148
],
[
1148,
... | [
[
[
"Trimipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
]
],
[
[
"Trimipramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Epinephrine"
],
[
"Epine... | Trimipramine may lead to a major life threatening interaction when taken with Epinephrine and Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol
Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may ... |
DB00352 | DB08913 | 482 | 1,186 | [
"DDInter1814",
"DDInter1561"
] | Tioguanine | Radium Ra 223 dichloride | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Radium Ra 223 Dichloride is a radiopharmaceutical containing the radioisotope radium-223 that emits short range but high linear energy alpha particles. As a cation, radium mimics calicum and binds to hydroxyapatite, which is a bone mineral found in areas of high bone turnover as seen in bone metastases. It was first ap... | Moderate | 1 | [
[
[
482,
24,
1186
]
],
[
[
482,
21,
28722
],
[
28722,
60,
1186
]
],
[
[
482,
24,
37
],
[
37,
24,
1186
]
],
[
[
482,
24,
1583
],
[
1583,
... | [
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
]
],
[
[
"Tioguanine",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect)... | Tioguanine (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Radium Ra 223 dichloride (Compound)
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Lomustine and Lomustine may cause a moderate interaction that could exacerbate diseases when taken with R... |
DB00402 | DB04837 | 1,407 | 649 | [
"DDInter685",
"DDInter407"
] | Eszopiclone | Clofedanol | Eszopiclone, marketed by Sepracor under the brand-name Lunesta, is a nonbenzodiazepine hypnotic drug used to treat insomnia. It is the active stereoisomer of zopiclone, belonging to the class of drugs known as _cyclopyrrolones_.[A179638,L6850] Cyclopyrrolone drugs demonstrate high efficacy and low toxicity, offering a ... | Clofedanol is a centrally-acting cough suppressant available in Canada under the trade name Ulone. It is not available in the United States. | Moderate | 1 | [
[
[
1407,
24,
649
]
],
[
[
1407,
24,
1376
],
[
1376,
24,
649
]
],
[
[
1407,
24,
832
],
[
832,
40,
649
]
],
[
[
1407,
63,
701
],
[
701,
... | [
[
[
"Eszopiclone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
]
],
[
[
"Eszopiclone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
... | Eszopiclone may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Eszopiclone may cause a moderate interaction that could exacerbate diseases when taken with Tripelenn... |
DB00342 | DB12245 | 1,181 | 823 | [
"DDInter1770",
"DDInter1863"
] | Terfenadine | Triclabendazole | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common li... | Moderate | 1 | [
[
[
1181,
24,
823
]
],
[
[
1181,
23,
1247
],
[
1247,
23,
823
]
],
[
[
1181,
24,
1612
],
[
1612,
24,
823
]
],
[
[
1181,
25,
918
],
[
918,
... | [
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Terfenadine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
... | Terfenadine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Fostem... |
DB00086 | DB01404 | 1,167 | 757 | [
"DDInter1712",
"DDInter820"
] | Streptokinase | Ginseng | Streptokinase, is a sterile, purified preparation of a bacterial protein elaborated by group C (beta) -hemolytic streptococci. | Ginseng is promoted as an adaptogen (a product that increases the body's resistance to stress), one which can to a certain extent be supported with reference to its anticarcinogenic and antioxidant properties. Ginseng is also known to contain phytoestrogens. | Moderate | 1 | [
[
[
1167,
24,
757
]
],
[
[
1167,
24,
578
],
[
578,
63,
757
]
],
[
[
1167,
25,
553
],
[
553,
24,
757
]
],
[
[
1167,
25,
256
],
[
256,
... | [
[
[
"Streptokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginseng"
]
],
[
[
"Streptokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[... | Streptokinase may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Ginseng
Streptokinase may lead to a major life threatening interaction when taken with Fondaparinux and Fondaparinux may... |
DB09268 | DB11978 | 1,662 | 124 | [
"DDInter1464",
"DDInter822"
] | Picosulfuric acid | Glasdegib | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Moderate | 1 | [
[
[
1662,
24,
124
]
],
[
[
1662,
63,
1247
],
[
1247,
23,
124
]
],
[
[
1662,
63,
1079
],
[
1079,
24,
124
]
],
[
[
1662,
24,
180
],
[
180,
... | [
[
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfamethoxazo... | Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB00361 | DB01764 | 134 | 805 | [
"DDInter1939",
"DDInter469"
] | Vinorelbine | Dalfopristin | Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990's for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-g... | Dalfopristin is a combination of two antibiotics (Dalfopristin and quinupristin) used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. It is not effective against Enterococcus faecalis infections. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome ... | Moderate | 1 | [
[
[
134,
24,
805
]
],
[
[
134,
6,
8374
],
[
8374,
45,
805
]
],
[
[
134,
63,
1101
],
[
1101,
23,
805
]
],
[
[
134,
24,
283
],
[
283,
... | [
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dalfopristin"
]
],
[
[
"Vinorelbine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compoun... | Vinorelbine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dalfopristin (Compound)
Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Dalfopristin
Vinorelbine ma... |
DB06210 | DB09272 | 72 | 412 | [
"DDInter631",
"DDInter632"
] | Eltrombopag | Eluxadoline | Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelet... | Eluxadoline is a mixed mu-opioid receptor agonist, kappa-opioid receptor agonist, and a-delta opioid receptor antagonist indicated for use in diarrhea-predominant irritable bowel syndrome (IBS-D). The mu-, kappa-, and delta-opioid receptors mediate endogenous and exogenous opioid response in the central nervous system ... | Major | 2 | [
[
[
72,
25,
412
]
],
[
[
72,
23,
74
],
[
74,
24,
412
]
],
[
[
72,
24,
791
],
[
791,
63,
412
]
],
[
[
72,
63,
700
],
[
700,
24,
... | [
[
[
"Eltrombopag",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eluxadoline"
]
],
[
[
"Eltrombopag",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Boceprevir"
],
[
"Boceprevi... | Eltrombopag may cause a minor interaction that can limit clinical effects when taken with Boceprevir and Boceprevir may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Voxilaprevir and Vox... |
DB01268 | DB12130 | 1,151 | 1,017 | [
"DDInter1731",
"DDInter1094"
] | Sunitinib | Lorlatinib | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
1151,
24,
1017
]
],
[
[
1151,
24,
1612
],
[
1612,
23,
1017
]
],
[
[
1151,
64,
1101
],
[
1101,
23,
1017
]
],
[
[
1151,
63,
590
],
[
590... | [
[
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
],
[
... | Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Sunitinib may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a ... |
DB00704 | DB01098 | 267 | 14 | [
"DDInter1263",
"DDInter1622"
] | Naltrexone | Rosuvastatin | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin... | Moderate | 1 | [
[
[
267,
24,
14
]
],
[
[
267,
24,
671
],
[
671,
24,
14
]
],
[
[
267,
7,
3163
],
[
3163,
46,
14
]
],
[
[
267,
7,
2900
],
[
2900,
57,
... | [
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
]
],
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
],
[... | Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin
Naltrexone (Compound) upregulates TSC22D3 (Gene) and TSC22D3 (Gene) is upregulated by Rosuvastatin (Compound... |
DB01001 | DB12245 | 688 | 823 | [
"DDInter1632",
"DDInter1863"
] | Salbutamol | Triclabendazole | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common li... | Moderate | 1 | [
[
[
688,
24,
823
]
],
[
[
688,
23,
1247
],
[
1247,
23,
823
]
],
[
[
688,
62,
112
],
[
112,
23,
823
]
],
[
[
688,
24,
1612
],
[
1612,
... | [
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Salbutamol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],... | Salbutamol may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole
Salbutamol may cause a minor interaction that can limit clinical effects when taken with Metronidaz... |
DB01085 | DB12267 | 562 | 1,476 | [
"DDInter1465",
"DDInter233"
] | Pilocarpine | Brigatinib | A naturally occurring alkaloid derived from the _Pilocarpus_ plants, pilocarpine is a muscarinic acetylcholine agonist.[A262016, A262036] Pilocarpine is associated with parasympathomimetic effects by selectively working on muscarinic receptors. Pilocarpine is used to treat dry mouth and various ophthalmic conditions, i... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
562,
24,
1476
]
],
[
[
562,
24,
1276
],
[
1276,
24,
1476
]
],
[
[
562,
63,
770
],
[
770,
24,
1476
]
],
[
[
562,
24,
1011
],
[
1011,
... | [
[
[
"Pilocarpine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Pilocarpine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alectinib"
],
[
... | Pilocarpine may cause a moderate interaction that could exacerbate diseases when taken with Alectinib and Alectinib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Pilocarpine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thali... |
DB00349 | DB01105 | 902 | 222 | [
"DDInter401",
"DDInter1665"
] | Clobazam | Sibutramine | Clobazam belongs to the 1,5-benzodiazepine class of drugs and is marketed under different names, Onfi, Frisium, Urbanyl, and others.. Clobazam was first synthesized in 1966 and first published in 1969, following the incidental synthesis and discovery of the first benzodiazepine chlordiazepoxide in the 1950s. Unlike old... | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Moderate | 1 | [
[
[
902,
24,
222
]
],
[
[
902,
6,
8374
],
[
8374,
45,
222
]
],
[
[
902,
21,
28852
],
[
28852,
60,
222
]
],
[
[
902,
63,
600
],
[
600,
... | [
[
[
"Clobazam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]
],
[
[
"Clobazam",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Clobazam (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sibutramine (Compound)
Clobazam (Compound) causes Leukopenia (Side Effect) and Leukopenia (Side Effect) is caused by Sibutramine (Compound)
Clobazam may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluco... |
DB01278 | DB14276 | 1,021 | 1,631 | [
"DDInter1506",
"DDInter1892"
] | Pramlintide | Turmeric | Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes. | Turmeric is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug. | Moderate | 1 | [
[
[
1021,
24,
1631
]
],
[
[
1021,
63,
473
],
[
473,
24,
1631
]
],
[
[
1021,
24,
1254
],
[
1254,
24,
1631
]
],
[
[
1021,
63,
473
],
[
473,
... | [
[
[
"Pramlintide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Turmeric"
]
],
[
[
"Pramlintide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
],
[
... | Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Turmeric
Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine a... |
DB00582 | DB00637 | 1,622 | 1,557 | [
"DDInter1946",
"DDInter128"
] | Voriconazole | Astemizole | Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increase... | Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. | Major | 2 | [
[
[
1622,
25,
1557
]
],
[
[
1622,
6,
21998
],
[
21998,
45,
1557
]
],
[
[
1622,
23,
112
],
[
112,
62,
1557
]
],
[
[
1622,
24,
770
],
[
770,... | [
[
[
"Voriconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Astemizole"
]
],
[
[
"Voriconazole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A7-CYP3A51P"
],
[
"CYP3A7-CYP3A51P",
"{u} (Gene) is bound by {v} (Comp... | Voriconazole (Compound) binds CYP3A7-CYP3A51P (Gene) and CYP3A7-CYP3A51P (Gene) is bound by Astemizole (Compound)
Voriconazole may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Astem... |
DB00446 | DB01112 | 597 | 665 | [
"DDInter351",
"DDInter335"
] | Chloramphenicol | Cefuroxime | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, gonorrhea, and haemophilus. | Moderate | 1 | [
[
[
597,
24,
665
]
],
[
[
597,
24,
1462
],
[
1462,
1,
665
]
],
[
[
597,
63,
149
],
[
149,
40,
665
]
],
[
[
597,
24,
164
],
[
164,
40... | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefuroxime"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefditoren"
]... | Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Cefditoren and Cefditoren (Compound) resembles Cefuroxime (Compound)
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Ceftazidime and Ceftazidime (Compound) resembles Cefuroxime... |
DB00252 | DB12010 | 362 | 214 | [
"DDInter1460",
"DDInter785"
] | Phenytoin | Fostamatinib | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for ... | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Major | 2 | [
[
[
362,
25,
214
]
],
[
[
362,
25,
976
],
[
976,
24,
214
]
],
[
[
362,
24,
723
],
[
723,
24,
214
]
],
[
[
362,
40,
307
],
[
307,
24,... | [
[
[
"Phenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostamatinib"
]
],
[
[
"Phenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u}... | Phenytoin may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may caus... |
DB00631 | DB10795 | 372 | 221 | [
"DDInter405",
"DDInter1486"
] | Clofarabine | Poliovirus type 1 antigen (formaldehyde inactivated) | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Poliovirus type 1 antigen is a suspension of poliovirus Type 1 (Mahoney) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by poliovirus Type 1. The vaccine contains purified and inactivated poliovirus type 1 that were grown from a c... | Moderate | 1 | [
[
[
372,
24,
221
]
],
[
[
372,
64,
581
],
[
581,
24,
221
]
],
[
[
372,
24,
350
],
[
350,
24,
221
]
],
[
[
372,
63,
599
],
[
599,
24,... | [
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Clofarabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
... | Clofarabine may lead to a major life threatening interaction when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Clofarabine may cause a moderate interaction that could exacerbate diseases when tak... |
DB01149 | DB12267 | 851 | 1,476 | [
"DDInter1274",
"DDInter233"
] | Nefazodone | Brigatinib | Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or ev... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Major | 2 | [
[
[
851,
25,
1476
]
],
[
[
851,
25,
1135
],
[
1135,
23,
1476
]
],
[
[
851,
63,
168
],
[
168,
23,
1476
]
],
[
[
851,
64,
629
],
[
629,
... | [
[
[
"Nefazodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
]
],
[
[
"Nefazodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may... | Nefazodone may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Nefazodone may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a mi... |
DB06292 | DB11255 | 549 | 1,371 | [
"DDInter474",
"DDInter374"
] | Dapagliflozin | Chromium picolinate | Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tu... | Chromium picolinate has a chemical formula CrPic3 and reddish-pink color. It is a coordination complex consisting of chromium(III) and picolinic acid. Chromium picolinate is used as a nutritional supplement for optimal insulin function in patients with Type 2 diabetes or promotion of weight loss. Chromium ions are show... | Moderate | 1 | [
[
[
549,
24,
1371
]
],
[
[
549,
63,
245
],
[
245,
24,
1371
]
],
[
[
549,
24,
1296
],
[
1296,
24,
1371
]
],
[
[
549,
1,
1344
],
[
1344,
... | [
[
[
"Dapagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chromium picolinate"
]
],
[
[
"Dapagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"... | Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Chromium picolinate
Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Insu... |
DB00620 | DB01097 | 175 | 1,377 | [
"DDInter1855",
"DDInter1033"
] | Triamcinolone | Leflunomide | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermat... | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Major | 2 | [
[
[
175,
25,
1377
]
],
[
[
175,
5,
11577
],
[
11577,
44,
1377
]
],
[
[
175,
18,
18226
],
[
18226,
57,
1377
]
],
[
[
175,
21,
28701
],
[
28... | [
[
[
"Triamcinolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Triamcinolone",
"{u} (Compound) treats {v} (Disease)",
"rheumatoid arthritis"
],
[
"rheumatoid arthritis",
"{u} (Disease) i... | Triamcinolone (Compound) treats rheumatoid arthritis (Disease) and rheumatoid arthritis (Disease) is treated by Leflunomide (Compound)
Triamcinolone (Compound) downregulates GDF15 (Gene) and GDF15 (Gene) is downregulated by Leflunomide (Compound)
Triamcinolone (Compound) causes Discomfort (Side Effect) and Discomfort (... |
DB00197 | DB13879 | 1,324 | 1,043 | [
"DDInter1881",
"DDInter824"
] | Troglitazone | Glecaprevir | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Glecaprevir is a direct acting antiviral agent and Hepatitis C virus (HCV) NS3/4A protease inhibitor that targets the the viral RNA replication. In combination with , glecaprevir is a useful therapy for patients who experienced therapeutic failure from other NS3/4A protease inhibitors. It demonstrates a high genetic ba... | Moderate | 1 | [
[
[
1324,
24,
1043
]
],
[
[
1324,
24,
1135
],
[
1135,
23,
1043
]
],
[
[
1324,
24,
466
],
[
466,
24,
1043
]
],
[
[
1324,
23,
1101
],
[
1101... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glecaprevir"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Glecaprevir
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Dar... |
DB00222 | DB14731 | 245 | 1,518 | [
"DDInter825",
"DDInter1741"
] | Glimepiride | Tagraxofusp | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Tagraxofusp is a CD123-directed cytotoxin. It is a fusion protein composed of a human interleukin-3 (IL-3) that is genetically fused to the catalytic and translocation domains of truncated diphtheria toxin (DT) produced in _Escherichia coli_.[A253762, A253887, L43702] Tagraxofusp received its first global approval by t... | Moderate | 1 | [
[
[
245,
24,
1518
]
],
[
[
245,
24,
123
],
[
123,
24,
1518
]
],
[
[
245,
63,
176
],
[
176,
24,
1518
]
],
[
[
245,
40,
1411
],
[
1411,
... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tagraxofusp"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
],
[
... | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Exenatide and Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Tagraxofusp
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and... |
DB00443 | DB00685 | 251 | 1,299 | [
"DDInter195",
"DDInter1887"
] | Betamethasone | Trovafloxacin | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective again... | Major | 2 | [
[
[
251,
25,
1299
]
],
[
[
251,
25,
872
],
[
872,
40,
1299
]
],
[
[
251,
21,
29093
],
[
29093,
60,
1299
]
],
[
[
251,
63,
1648
],
[
1648,
... | [
[
[
"Betamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trovafloxacin"
]
],
[
[
"Betamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gemifloxacin"
],
[
"Gemifloxacin",... | Betamethasone may lead to a major life threatening interaction when taken with Gemifloxacin and Gemifloxacin (Compound) resembles Trovafloxacin (Compound)
Betamethasone (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Trovafloxacin (Compound)
Betamethasone may cause a moderate interaction ... |
DB00975 | DB08875 | 1,317 | 1,618 | [
"DDInter573",
"DDInter262"
] | Dipyridamole | Cabozantinib | A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752) | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Major | 2 | [
[
[
1317,
25,
1618
]
],
[
[
1317,
24,
41
],
[
41,
63,
1618
]
],
[
[
1317,
24,
222
],
[
222,
24,
1618
]
],
[
[
1317,
63,
529
],
[
529,
... | [
[
[
"Dipyridamole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Dipyridamole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
],
[
... | Dipyridamole may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran and Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Dipyridamole may cause a moderate interaction that could exacerbate diseases when taken with Sibut... |
DB09280 | DB11915 | 1,604 | 1,293 | [
"DDInter1101",
"DDInter1909"
] | Lumacaftor | Valbenazine | Lumacaftor is a drug used in combination with as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Con... | Valbenazine is a modified metabolite of [tetrabenazine], and it is currently being approved for the treatment of various movement disorders, particularly tardive dyskinesia and chorea associated with Huntington's disease.[L47885,A261135] Tardive dyskinesia has long been regarded as a consequence of anti-dopamine recept... | Major | 2 | [
[
[
1604,
25,
1293
]
],
[
[
1604,
64,
1151
],
[
1151,
24,
1293
]
],
[
[
1604,
63,
477
],
[
477,
24,
1293
]
],
[
[
1604,
25,
159
],
[
159,
... | [
[
[
"Lumacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Valbenazine"
]
],
[
[
"Lumacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sunitinib"
],
[
"Sunitinib",
"{u} ma... | Lumacaftor may lead to a major life threatening interaction when taken with Sunitinib and Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Valbenazine
Lumacaftor may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol and Cilostazol may cause a... |
DB01174 | DB09036 | 697 | 812 | [
"DDInter1442",
"DDInter1668"
] | Phenobarbital | Siltuximab | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. | Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6). I... | Moderate | 1 | [
[
[
697,
24,
812
]
],
[
[
697,
25,
792
],
[
792,
24,
812
]
],
[
[
697,
63,
1031
],
[
1031,
24,
812
]
],
[
[
697,
62,
608
],
[
608,
2... | [
[
[
"Phenobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Siltuximab"
]
],
[
[
"Phenobarbital",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rivaroxaban"
],
[
"Riv... | Phenobarbital may lead to a major life threatening interaction when taken with Rivaroxaban and Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Siltuximab
Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophyllin... |
DB00951 | DB06772 | 1,072 | 310 | [
"DDInter986",
"DDInter259"
] | Isoniazid | Cabazitaxel | Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. | Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more ... | Moderate | 1 | [
[
[
1072,
24,
310
]
],
[
[
1072,
24,
973
],
[
973,
24,
310
]
],
[
[
1072,
6,
3486
],
[
3486,
45,
310
]
],
[
[
1072,
21,
28701
],
[
28701,
... | [
[
[
"Isoniazid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Isoniazid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],
[
... | Isoniazid may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Isoniazid (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Cabazitaxel (Compound)
Isoniazid (Compoun... |
DB06589 | DB14881 | 1,250 | 180 | [
"DDInter1400",
"DDInter1329"
] | Pazopanib | Oliceridine | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid recepto... | Moderate | 1 | [
[
[
1250,
24,
180
]
],
[
[
1250,
62,
112
],
[
112,
23,
180
]
],
[
[
1250,
63,
401
],
[
401,
24,
180
]
],
[
[
1250,
24,
124
],
[
124,
... | [
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Pazopanib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Pazopanib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Oliceridine
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Pro... |
DB00400 | DB06077 | 353 | 879 | [
"DDInter843",
"DDInter1102"
] | Griseofulvin | Lumateperone | An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections. | Schizophrenia is a complex mental illness and impacts approximately 1% of the population. Although there are several antipsychotics including [aripiprazole], [paliperidone] and [clozapine] available for clinical use, they are generally accompanied by significant metabolic and/or neurological adverse effects. Lumatepero... | Major | 2 | [
[
[
353,
25,
879
]
],
[
[
353,
24,
214
],
[
214,
63,
879
]
],
[
[
353,
24,
392
],
[
392,
24,
879
]
],
[
[
353,
63,
79
],
[
79,
24,
... | [
[
[
"Griseofulvin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lumateperone"
]
],
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
"Fo... | Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Lumateperone
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib a... |
DB00687 | DB01232 | 870 | 1,327 | [
"DDInter747",
"DDInter1640"
] | Fludrocortisone | Saquinavir | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due... | Moderate | 1 | [
[
[
870,
24,
1327
]
],
[
[
870,
63,
798
],
[
798,
40,
1327
]
],
[
[
870,
24,
915
],
[
915,
40,
1327
]
],
[
[
870,
21,
28936
],
[
28936,
... | [
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saquinavir"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nelfinavir"
]... | Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Nelfinavir and Nelfinavir (Compound) resembles Saquinavir (Compound)
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Atazanavir and Atazanavir (Compound) resembles Saquinavir (... |
DB00731 | DB01285 | 1,144 | 708 | [
"DDInter1269",
"DDInter445"
] | Nateglinide | Corticotropin | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis. | Moderate | 1 | [
[
[
1144,
24,
708
]
],
[
[
1144,
24,
455
],
[
455,
23,
708
]
],
[
[
1144,
24,
659
],
[
659,
62,
708
]
],
[
[
1144,
63,
245
],
[
245,
... | [
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
],
... | Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a minor interaction that can limit clinical effects when taken with Corticotropin
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vil... |
DB00836 | DB00845 | 543 | 1,490 | [
"DDInter1088",
"DDInter406"
] | Loperamide | Clofazimine | Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as [diphenoxyla... | Clofazimine is a highly lipophilic antimicrobial riminophenazine dye used in combination with other agents, such as [dapsone], for the treatment of leprosy. It was originally described in 1957 and was the prototypical riminophenazine dye - a bright-red dye that, in its clinical use, results in long-lasting discoloratio... | Moderate | 1 | [
[
[
543,
24,
1490
]
],
[
[
543,
6,
4973
],
[
4973,
45,
1490
]
],
[
[
543,
21,
28787
],
[
28787,
60,
1490
]
],
[
[
543,
24,
112
],
[
112,
... | [
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofazimine"
]
],
[
[
"Loperamide",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Loperamide (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Clofazimine (Compound)
Loperamide (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Clofazimine (Compound)
Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and... |
DB00682 | DB00948 | 126 | 1,681 | [
"DDInter1951",
"DDInter1207"
] | Warfarin | Mezlocillin | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Semisynthetic ampicillin-derived acylureido penicillin. It has been proposed for infections with certain anaerobes and may be useful in inner ear, bile, and CNS infections. | Moderate | 1 | [
[
[
126,
24,
1681
]
],
[
[
126,
64,
916
],
[
916,
1,
1681
]
],
[
[
126,
24,
514
],
[
514,
1,
1681
]
],
[
[
126,
63,
1667
],
[
1667,
... | [
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mezlocillin"
]
],
[
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dicloxacillin"
],
[
"Dicloxacil... | Warfarin may lead to a major life threatening interaction when taken with Dicloxacillin and Dicloxacillin (Compound) resembles Mezlocillin (Compound)
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Benzylpenicillin and Benzylpenicillin (Compound) resembles Mezlocillin (Compound)... |
DB00865 | DB09564 | 939 | 1,296 | [
"DDInter187",
"DDInter930"
] | Benzphetamine | Insulin degludec | A sympathomimetic agent with properties similar to dextroamphetamine. It is used in the treatment of obesity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222) | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Moderate | 1 | [
[
[
939,
24,
1296
]
],
[
[
939,
24,
1411
],
[
1411,
24,
1296
]
],
[
[
939,
63,
1645
],
[
1645,
24,
1296
]
],
[
[
939,
40,
508
],
[
508,
... | [
[
[
"Benzphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Benzphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
... | Benzphetamine may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Benzphetamine may cause a moderate interaction that could exacerbate diseases when taken with Metform... |
DB01087 | DB14509 | 1,520 | 1,399 | [
"DDInter1520",
"DDInter1081"
] | Primaquine | Lithium carbonate | An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Ad... | Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label]. | Moderate | 1 | [
[
[
1520,
24,
1399
]
],
[
[
1520,
24,
1374
],
[
1374,
24,
1399
]
],
[
[
1520,
63,
1010
],
[
1010,
24,
1399
]
],
[
[
1520,
62,
112
],
[
112... | [
[
[
"Primaquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Primaquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
],
... | Primaquine may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Primaquine may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine a... |
DB01409 | DB06702 | 1,415 | 573 | [
"DDInter1815",
"DDInter731"
] | Tiotropium | Fesoterodine | Tiotropium is a long-acting, antimuscarinic bronchodilator used in the management of chronic obstructive pulmonary disease (COPD) and asthma.[A180163,L7084,L7087,L7090,L7093] Tiotropium acts mainly on M3 muscarinic receptors located in the airways to produce smooth muscle relaxation and bronchodilation.[A180163,L7084,L... | Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome. | Moderate | 1 | [
[
[
1415,
24,
573
]
],
[
[
1415,
63,
211
],
[
211,
1,
573
]
],
[
[
1415,
6,
12523
],
[
12523,
45,
573
]
],
[
[
1415,
21,
28681
],
[
28681,... | [
[
[
"Tiotropium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fesoterodine"
]
],
[
[
"Tiotropium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolterodine"
],
[... | Tiotropium may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine and Tolterodine (Compound) resembles Fesoterodine (Compound)
Tiotropium (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Fesoterodine (Compound)
Tiotropium (Compound) causes Hypersensitivity (Side Effect) ... |
DB01764 | DB09074 | 805 | 1,362 | [
"DDInter469",
"DDInter1327"
] | Dalfopristin | Olaparib | Dalfopristin is a combination of two antibiotics (Dalfopristin and quinupristin) used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. It is not effective against Enterococcus faecalis infections. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome ... | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Major | 2 | [
[
[
805,
25,
1362
]
],
[
[
805,
63,
896
],
[
896,
24,
1362
]
],
[
[
805,
25,
1478
],
[
1478,
24,
1362
]
],
[
[
805,
24,
1619
],
[
1619,
... | [
[
[
"Dalfopristin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
]
],
[
[
"Dalfopristin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
],
[
"Etoposide... | Dalfopristin may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Dalfopristin may lead to a major life threatening interaction when taken with Ivacaftor and Ivacaftor may cause a ... |
DB00661 | DB12267 | 122 | 1,476 | [
"DDInter1928",
"DDInter233"
] | Verapamil | Brigatinib | Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina, and was the first calcium channel antagonist to be introduced into therapy in the early 1960s. It is a member of the non-dihydropyridine class of calcium channel blockers, which includes ... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Major | 2 | [
[
[
122,
25,
1476
]
],
[
[
122,
25,
1135
],
[
1135,
23,
1476
]
],
[
[
122,
24,
629
],
[
629,
24,
1476
]
],
[
[
122,
25,
1456
],
[
1456,
... | [
[
[
"Verapamil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
]
],
[
[
"Verapamil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may c... | Verapamil may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Verapamil may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a modera... |
DB00307 | DB09272 | 1,101 | 412 | [
"DDInter202",
"DDInter632"
] | Bexarotene | Eluxadoline | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Eluxadoline is a mixed mu-opioid receptor agonist, kappa-opioid receptor agonist, and a-delta opioid receptor antagonist indicated for use in diarrhea-predominant irritable bowel syndrome (IBS-D). The mu-, kappa-, and delta-opioid receptors mediate endogenous and exogenous opioid response in the central nervous system ... | Major | 2 | [
[
[
1101,
25,
412
]
],
[
[
1101,
24,
74
],
[
74,
24,
412
]
],
[
[
1101,
63,
1131
],
[
1131,
24,
412
]
],
[
[
1101,
23,
68
],
[
68,
6... | [
[
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eluxadoline"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Boceprevir"
],
[
"Boceprevi... | Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Boceprevir and Boceprevir may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Methysergide and Met... |
DB00682 | DB00861 | 126 | 914 | [
"DDInter1951",
"DDInter551"
] | Warfarin | Diflunisal | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Diflunisal, a salicylate derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with pharmacologic actions similar to other prototypical NSAIAs. Diflunisal possesses anti-inflammatory, analgesic and antipyretic activity. Though its mechanism of action has not been clearly established, most of its actions appear ... | Major | 2 | [
[
[
126,
25,
914
]
],
[
[
126,
1,
345
],
[
345,
1,
914
]
],
[
[
126,
23,
712
],
[
712,
63,
914
]
],
[
[
126,
6,
1829
],
[
1829,
45,
... | [
[
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diflunisal"
]
],
[
[
"Warfarin",
"{u} (Compound) resembles {v} (Compound)",
"Salsalate"
],
[
"Salsalate",
"{u} (Compound) resembles {v} (Compound)",
... | Warfarin (Compound) resembles Salsalate (Compound) and Salsalate (Compound) resembles Diflunisal (Compound)
Warfarin may cause a minor interaction that can limit clinical effects when taken with Olsalazine and Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Diflunisal
Warfarin... |
DB09280 | DB09291 | 1,604 | 741 | [
"DDInter1101",
"DDInter1615"
] | Lumacaftor | Rolapitant | Lumacaftor is a drug used in combination with as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Con... | Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its l... | Major | 2 | [
[
[
1604,
25,
741
]
],
[
[
1604,
64,
1135
],
[
1135,
23,
741
]
],
[
[
1604,
63,
479
],
[
479,
23,
741
]
],
[
[
1604,
25,
159
],
[
159,
... | [
[
[
"Lumacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rolapitant"
]
],
[
[
"Lumacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may... | Lumacaftor may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Rolapitant
Lumacaftor may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a mino... |
DB00593 | DB06372 | 1,464 | 259 | [
"DDInter695",
"DDInter1594"
] | Ethosuximide | Rilonacept | An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures. | Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold au... | Moderate | 1 | [
[
[
1464,
24,
259
]
],
[
[
1464,
24,
1619
],
[
1619,
63,
259
]
],
[
[
1464,
24,
478
],
[
478,
24,
259
]
],
[
[
1464,
63,
58
],
[
58,
... | [
[
[
"Ethosuximide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
]
],
[
[
"Ethosuximide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[... | Ethosuximide may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept
Ethosuximide may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilot... |
DB00618 | DB08938 | 1,572 | 1,384 | [
"DDInter498",
"DDInter1112"
] | Demeclocycline | Magaldrate | A tetracycline analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time. | Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market. | Moderate | 1 | [
[
[
1572,
24,
1384
]
],
[
[
1572,
63,
1252
],
[
1252,
23,
1384
]
],
[
[
1572,
24,
954
],
[
954,
23,
1384
]
],
[
[
1572,
40,
964
],
[
964,
... | [
[
[
"Demeclocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magaldrate"
]
],
[
[
"Demeclocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
],
... | Demeclocycline may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Demeclocycline may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapr... |
DB00207 | DB00927 | 1,570 | 1,559 | [
"DDInter157",
"DDInter712"
] | Azithromycin | Famotidine | Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration. It was initially approved by the FDA in 1991. It is primarily used for the treatment of respiratory, enteric and genitourinary infections and may be used instead of other macrolides for some sexually tra... | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</su... | Moderate | 1 | [
[
[
1570,
24,
1559
]
],
[
[
1570,
21,
28826
],
[
28826,
60,
1559
]
],
[
[
1570,
24,
1384
],
[
1384,
62,
1559
]
],
[
[
1570,
23,
112
],
[
1... | [
[
[
"Azithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
]
],
[
[
"Azithromycin",
"{u} (Compound) causes {v} (Side Effect)",
"Jaundice"
],
[
"Jaundice",
"{u} (Side Effect) is ca... | Azithromycin (Compound) causes Jaundice (Side Effect) and Jaundice (Side Effect) is caused by Famotidine (Compound)
Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Magaldrate and Magaldrate may cause a minor interaction that can limit clinical effects when taken with Famotid... |
DB00238 | DB11986 | 188 | 484 | [
"DDInter1285",
"DDInter648"
] | Nevirapine | Entrectinib | A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class. | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Major | 2 | [
[
[
188,
25,
484
]
],
[
[
188,
24,
466
],
[
466,
62,
484
]
],
[
[
188,
24,
1135
],
[
1135,
23,
484
]
],
[
[
188,
24,
510
],
[
510,
2... | [
[
[
"Nevirapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Entrectinib"
]
],
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
"Darolut... | Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Nalo... |
DB00780 | DB00792 | 551 | 832 | [
"DDInter1440",
"DDInter1878"
] | Phenelzine | Tripelennamine | Phenelzine, with the formula β-phenylethylhydrazine, is a monoamine oxidase inhibiting antidepressant that is effective in the treatment of panic disorder and social anxiety disorder. It was developed by Parke Davis and originally FDA approved on June 9th, 1961. It is currently approved under prescription by the name o... | A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically. | Moderate | 1 | [
[
[
551,
24,
832
]
],
[
[
551,
24,
100
],
[
100,
63,
832
]
],
[
[
551,
25,
1264
],
[
1264,
63,
832
]
],
[
[
551,
40,
11284
],
[
11284,
... | [
[
[
"Phenelzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
]
],
[
[
"Phenelzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],... | Phenelzine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine
Phenelzine may lead to a major life threatening interaction when taken with Doxepin and Doxepin ma... |
DB00095 | DB00544 | 66 | 970 | [
"DDInter623",
"DDInter757"
] | Efalizumab | Fluorouracil | Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It wa... | A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. | Moderate | 1 | [
[
[
66,
24,
970
]
],
[
[
66,
24,
147
],
[
147,
62,
970
]
],
[
[
66,
24,
1686
],
[
1686,
63,
970
]
],
[
[
66,
24,
141
],
[
141,
24,
... | [
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluorouracil"
]
],
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastine"
],
[... | Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine may cause a minor interaction that can limit clinical effects when taken with Fluorouracil
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Temozolomide and Te... |
DB05528 | DB05812 | 1,070 | 1,374 | [
"DDInter1228",
"DDInter8"
] | Mipomersen | Abiraterone | Mipomersen sodium, which was known as the investigational drug, isis-301012, is the salt form of a synthetic phosphorothioate oligonucleotide. Mipomersen sodium prevents the formation of apo B-100, resulting in a decrease in the levels of apolipoprotein B (apo B), low density lipoprotein (LDL), and total cholesterol. M... | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Major | 2 | [
[
[
1070,
25,
1374
]
],
[
[
1070,
64,
1555
],
[
1555,
24,
1374
]
],
[
[
1070,
25,
159
],
[
159,
63,
1374
]
],
[
[
1070,
25,
1593
],
[
1593... | [
[
[
"Mipomersen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abiraterone"
]
],
[
[
"Mipomersen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oxaliplatin"
],
[
"Oxaliplatin",
"{u... | Mipomersen may lead to a major life threatening interaction when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone
Mipomersen may lead to a major life threatening interaction when taken with Larotrectinib and Larotrectinib may cause a mode... |
DB09312 | DB10316 | 967 | 334 | [
"DDInter106",
"DDInter1248"
] | Antithymocyte immunoglobulin (rabbit) | Mumps virus strain B level jeryl lynn live antigen | Rabbit anti-thymocyte globulin. Thymoglobulin is a polyclonal antibody that suppresses certain types of immune cells responsible for acute organ rejection in transplant patients. Thymoglobulin is a mixture of antibodies intended to bind to various cell surface antigens. The most common mode of action of Thymoglobulin i... | Mumps virus strain B level jeryl lynn live antigen is a live attenuated virus vaccine for subcutenous injection. It is an active immunization against mumps, which is a common childhood disease. | Major | 2 | [
[
[
967,
25,
334
]
],
[
[
967,
64,
1057
],
[
1057,
25,
334
]
],
[
[
967,
25,
1011
],
[
1011,
25,
334
]
],
[
[
967,
63,
599
],
[
599,
... | [
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may lead to a major life threatening inte... | Antilymphocyte immunoglobulin (horse) may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen
Antilymphocyte immunoglobulin (horse) may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening ... |
DB08826 | DB12674 | 1,292 | 975 | [
"DDInter489",
"DDInter1105"
] | Deferiprone | Lurbinectedin | Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA ap... | Lurbinectedin is a DNA alkylating agent that has been investigated in the treatment of a variety of cancers, including mesothelioma, chronic lymphocytic leukemia (CLL), breast cancer, and small-cell lung cancer (SCLC). It is a derivative of the marine-derived agent ecteinascidin ([trabectedin]), an anticancer agent fou... | Major | 2 | [
[
[
1292,
25,
975
]
],
[
[
1292,
64,
1488
],
[
1488,
24,
975
]
],
[
[
1292,
25,
1362
],
[
1362,
24,
975
]
],
[
[
1292,
25,
351
],
[
351,
... | [
[
[
"Deferiprone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lurbinectedin"
]
],
[
[
"Deferiprone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fludarabine"
],
[
"Fludarabine",
... | Deferiprone may lead to a major life threatening interaction when taken with Fludarabine and Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Deferiprone may lead to a major life threatening interaction when taken with Olaparib and Olaparib may cause a moderate i... |
DB00682 | DB06777 | 126 | 780 | [
"DDInter1951",
"DDInter348"
] | Warfarin | Chenodeoxycholic acid | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Chenodeoxycholic acid (or Chenodiol) is an epimer of ursodeoxycholic acid (DB01586). Chenodeoxycholic acid is a bile acid naturally found in the body. It works by dissolving the cholesterol that makes gallstones and inhibiting production of cholesterol in the liver and absorption in the intestines, which helps to decre... | Moderate | 1 | [
[
[
126,
24,
780
]
],
[
[
126,
6,
8374
],
[
8374,
45,
780
]
],
[
[
126,
24,
384
],
[
384,
63,
780
]
],
[
[
126,
25,
1534
],
[
1534,
... | [
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chenodeoxycholic acid"
]
],
[
[
"Warfarin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Comp... | Warfarin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Chenodeoxycholic acid (Compound)
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Chenodeoxycholic acid
... |
DB00444 | DB06414 | 63 | 655 | [
"DDInter1765",
"DDInter703"
] | Teniposide | Etravirine | Teniposide is a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells ... | Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 10... | Moderate | 1 | [
[
[
63,
24,
655
]
],
[
[
63,
6,
6017
],
[
6017,
45,
655
]
],
[
[
63,
21,
28680
],
[
28680,
60,
655
]
],
[
[
63,
63,
168
],
[
168,
23... | [
[
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
]
],
[
[
"Teniposide",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",... | Teniposide (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Etravirine (Compound)
Teniposide (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Etravirine (Compound)
Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may... |
DB00831 | DB11186 | 1,178 | 1,609 | [
"DDInter1866",
"DDInter1427"
] | Trifluoperazine | Pentoxyverine | A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic. | Pentoxyverine, also referred to as carbetapentane, is a non-opioid central acting antitussive with antimuscarinic, anticonvulsant , and local anesthetic properties. It is an active ingredient in over-the-counter cough suppressants in combination with guaifenesin and H1-receptor antagonists . Pentoxyverine acts on sigma... | Moderate | 1 | [
[
[
1178,
24,
1609
]
],
[
[
1178,
1,
508
],
[
508,
24,
1609
]
],
[
[
1178,
35,
104
],
[
104,
24,
1609
]
],
[
[
1178,
63,
999
],
[
999,
... | [
[
[
"Trifluoperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Trifluoperazine",
"{u} (Compound) resembles {v} (Compound)",
"Promazine"
],
[
"Promazine",
"{u} may caus... | Trifluoperazine (Compound) resembles Promazine (Compound) and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Trifluoperazine (Compound) resembles Methdilazine (Compound) and Trifluoperazine may cause a moderate interaction that could exacerbate diseases when take... |
DB00224 | DB00530 | 215 | 1,195 | [
"DDInter917",
"DDInter667"
] | Indinavir | Erlotinib | A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem] | Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR)... | Moderate | 1 | [
[
[
215,
24,
1195
]
],
[
[
215,
24,
883
],
[
883,
40,
1195
]
],
[
[
215,
6,
12523
],
[
12523,
45,
1195
]
],
[
[
215,
7,
7245
],
[
7245,
... | [
[
[
"Indinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erlotinib"
]
],
[
[
"Indinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gefitinib"
],
[
... | Indinavir may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib (Compound) resembles Erlotinib (Compound)
Indinavir (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Erlotinib (Compound)
Indinavir (Compound) upregulates SSBP2 (Gene) and SSBP2 (Gene) is upregu... |
DB00414 | DB00927 | 590 | 1,559 | [
"DDInter16",
"DDInter712"
] | Acetohexamide | Famotidine | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</su... | Moderate | 1 | [
[
[
590,
24,
1559
]
],
[
[
590,
24,
886
],
[
886,
23,
1559
]
],
[
[
590,
24,
935
],
[
935,
62,
1559
]
],
[
[
590,
63,
831
],
[
831,
... | [
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketorolac"
],
... | Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Ketorolac and Ketorolac may cause a minor interaction that can limit clinical effects when taken with Famotidine
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Ketoprofen and Keto... |
DB01045 | DB08896 | 463 | 292 | [
"DDInter1590",
"DDInter1576"
] | Rifampicin | Regorafenib | A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation ... | Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in Ap... | Moderate | 1 | [
[
[
463,
24,
292
]
],
[
[
463,
63,
79
],
[
79,
1,
292
]
],
[
[
463,
6,
6017
],
[
6017,
45,
292
]
],
[
[
463,
23,
549
],
[
549,
23,
... | [
[
[
"Rifampicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Regorafenib"
]
],
[
[
"Rifampicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
[
... | Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib (Compound) resembles Regorafenib (Compound)
Rifampicin (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Regorafenib (Compound)
Rifampicin may cause a minor interaction that can limit clinical e... |
DB00681 | DB01610 | 1,287 | 248 | [
"DDInter85",
"DDInter1912"
] | Amphotericin B | Valganciclovir | Amphotericin B shows a high order of in vitro activity against many species of fungi. Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by concentrations of amphot... | Valganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections. As the L-valyl ester of ganciclovir, it is actually a prodrug for ganciclovir. After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases. | Moderate | 1 | [
[
[
1287,
24,
248
]
],
[
[
1287,
24,
563
],
[
563,
1,
248
]
],
[
[
1287,
21,
29209
],
[
29209,
60,
248
]
],
[
[
1287,
63,
372
],
[
372,
... | [
[
[
"Amphotericin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
]
],
[
[
"Amphotericin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
... | Amphotericin B may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir and Ganciclovir (Compound) resembles Valganciclovir (Compound)
Amphotericin B (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Valganciclovir (Compound)
Amphotericin B may cause a m... |
DB00683 | DB11186 | 1,382 | 1,609 | [
"DDInter1212",
"DDInter1427"
] | Midazolam | Pentoxyverine | Midazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties. It belongs to a class of drugs called _benzodiazepines_. This drug is unique from others in this class due to its rapid onset of effects and short duration of action. Midazola... | Pentoxyverine, also referred to as carbetapentane, is a non-opioid central acting antitussive with antimuscarinic, anticonvulsant , and local anesthetic properties. It is an active ingredient in over-the-counter cough suppressants in combination with guaifenesin and H1-receptor antagonists . Pentoxyverine acts on sigma... | Moderate | 1 | [
[
[
1382,
24,
1609
]
],
[
[
1382,
24,
104
],
[
104,
24,
1609
]
],
[
[
1382,
63,
999
],
[
999,
24,
1609
]
],
[
[
1382,
1,
523
],
[
523,
... | [
[
[
"Midazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Midazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[... | Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine... |
DB00959 | DB01396 | 1,486 | 1,482 | [
"DDInter1191",
"DDInter553"
] | Methylprednisolone | Digitoxin | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | A cardiac glycoside sometimes used in place of digoxin. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. (From Martindale, The Extra Pharmacopoeia, 30th ed, p665) | Moderate | 1 | [
[
[
1486,
24,
1482
]
],
[
[
1486,
63,
1252
],
[
1252,
1,
1482
]
],
[
[
1486,
6,
8374
],
[
8374,
45,
1482
]
],
[
[
1486,
7,
3603
],
[
3603,... | [
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digitoxin"
]
],
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
... | Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin (Compound) resembles Digitoxin (Compound)
Methylprednisolone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Digitoxin (Compound)
Methylprednisolone (Compound) upregulates ZFP36 (Gene) and... |
DB01005 | DB10583 | 995 | 949 | [
"DDInter894",
"DDInter415"
] | Hydroxyurea | Clostridium tetani toxoid antigen (formaldehyde inactivated) | Hydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928. It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. Although clinical evidence on the efficacy of hydroxyurea in certain conditions exists, h... | Clostridium tetani toxoid antigen (formaldehyde inactivated) is a vaccine for intramuscular injection. It is used for active immunization of children 7 years of age or older, and adults, for prevention of tetanus. The toxoid in the Clostridium tetani culture is grown and detoxified followed by purification via ammonium... | Moderate | 1 | [
[
[
995,
24,
949
]
],
[
[
995,
63,
589
],
[
589,
24,
949
]
],
[
[
995,
25,
1377
],
[
1377,
24,
949
]
],
[
[
995,
24,
1488
],
[
1488,
... | [
[
[
"Hydroxyurea",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
]
],
[
[
"Hydroxyurea",
"{u} may cause a moderate interaction that could exacerbate diseases when... | Hydroxyurea may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated)
Hydroxyurea may lead to a major life threatening interaction wh... |
DB09065 | DB11853 | 760 | 230 | [
"DDInter424",
"DDInter1577"
] | Cobicistat | Relugolix | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under th... | Major | 2 | [
[
[
760,
25,
230
]
],
[
[
760,
64,
129
],
[
129,
23,
230
]
],
[
[
760,
62,
1101
],
[
1101,
23,
230
]
],
[
[
760,
25,
1476
],
[
1476,
... | [
[
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Relugolix"
]
],
[
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u... | Cobicistat may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Relugolix
Cobicistat may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a... |
DB00218 | DB00342 | 1,176 | 1,181 | [
"DDInter1247",
"DDInter1770"
] | Moxifloxacin | Terfenadine | Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment. | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | Major | 2 | [
[
[
1176,
25,
1181
]
],
[
[
1176,
23,
112
],
[
112,
62,
1181
]
],
[
[
1176,
1,
872
],
[
872,
63,
1181
]
],
[
[
1176,
24,
286
],
[
286,
... | [
[
[
"Moxifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Terfenadine"
]
],
[
[
"Moxifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metr... | Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Terfenadine
Moxifloxacin (Compound) resembles Gemifloxacin (Compound) and Gemifloxacin may cause a moderate interaction... |
DB06273 | DB09054 | 980 | 384 | [
"DDInter1824",
"DDInter905"
] | Tocilizumab | Idelalisib | Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 J... | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
980,
24,
384
]
],
[
[
980,
24,
1627
],
[
1627,
62,
384
]
],
[
[
980,
63,
289
],
[
289,
24,
384
]
],
[
[
980,
24,
788
],
[
788,
2... | [
[
[
"Tocilizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Tocilizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
],
[... | Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Cerivastatin and Ce... |
DB00439 | DB08816 | 289 | 578 | [
"DDInter341",
"DDInter1802"
] | Cerivastatin | Ticagrelor | On August 8, 2001 the U.S. Food and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal rhabdomyolysis, a severe adverse reaction from this cholesterol-lowering (lipid-lowering) product. It has also been withdrawn from the Cana... | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Moderate | 1 | [
[
[
289,
24,
578
]
],
[
[
289,
24,
723
],
[
723,
24,
578
]
],
[
[
289,
24,
868
],
[
868,
63,
578
]
],
[
[
289,
63,
134
],
[
134,
24,... | [
[
[
"Cerivastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Cerivastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
... | Cerivastatin may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Cerivastatin may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and V... |
DB00026 | DB00526 | 1,184 | 1,555 | [
"DDInter94",
"DDInter1355"
] | Anakinra | Oxaliplatin | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta.... | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Moderate | 1 | [
[
[
1184,
24,
1555
]
],
[
[
1184,
24,
141
],
[
141,
24,
1555
]
],
[
[
1184,
24,
1136
],
[
1136,
63,
1555
]
],
[
[
1184,
63,
305
],
[
305,
... | [
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Floxuridine"
],
[
... | Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Floxuridine and Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Denosumab and Denosuma... |
DB01098 | DB06317 | 14 | 1,626 | [
"DDInter1622",
"DDInter630"
] | Rosuvastatin | Elotuzumab | Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin... | Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family... | Moderate | 1 | [
[
[
14,
24,
1626
]
],
[
[
14,
24,
973
],
[
973,
24,
1626
]
],
[
[
14,
63,
1463
],
[
1463,
24,
1626
]
],
[
[
14,
24,
310
],
[
310,
63... | [
[
[
"Rosuvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elotuzumab"
]
],
[
[
"Rosuvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],
... | Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab
Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Lovastatin and Lo... |
DB06616 | DB08904 | 594 | 375 | [
"DDInter224",
"DDInter342"
] | Bosutinib | Certolizumab pegol | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Major | 2 | [
[
[
594,
25,
375
]
],
[
[
594,
24,
200
],
[
200,
63,
375
]
],
[
[
594,
25,
1593
],
[
1593,
24,
375
]
],
[
[
594,
63,
66
],
[
66,
24,... | [
[
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
],
[
... | Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans and Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Bosutinib may lead to a major life threatening interaction when taken with Crizotinib and Cri... |
DB00783 | DB12267 | 1,438 | 1,476 | [
"DDInter679",
"DDInter233"
] | Estradiol | Brigatinib | Estradiol is a naturally occurring hormone circulating endogenously in females. It is commercially available in several hormone therapy products for managing conditions associated with reduced estrogen, such as vulvovaginal atrophy and hot flashes. Some available forms of estradiol include oral tablets, injections, vag... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
1438,
24,
1476
]
],
[
[
1438,
24,
629
],
[
629,
24,
1476
]
],
[
[
1438,
63,
176
],
[
176,
24,
1476
]
],
[
[
1438,
24,
1385
],
[
1385,
... | [
[
[
"Estradiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Estradiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[
... | Estradiol may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Estradiol may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insu... |
DB00241 | DB01114 | 288 | 272 | [
"DDInter257",
"DDInter362"
] | Butalbital | Chlorpheniramine | Butalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. It is a short-to-intermediate acting member of barbiturates that exhibit muscle-relaxing and anti-anxiety properties that produce central nervou... | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | Moderate | 1 | [
[
[
288,
24,
272
]
],
[
[
288,
24,
849
],
[
849,
63,
272
]
],
[
[
288,
24,
128
],
[
128,
24,
272
]
],
[
[
288,
1,
536
],
[
536,
24,
... | [
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
]
],
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
... | Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniram... |
DB00284 | DB01238 | 1,647 | 673 | [
"DDInter11",
"DDInter118"
] | Acarbose | Aripiprazole | Acarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines. It inhibits both pancreatic alpha-amylase and membrane-bound alpha-glucosidases - including intestinal glucoamylase, sucrase, maltase, and isomaltase - which are r... | Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects thr... | Moderate | 1 | [
[
[
1647,
24,
673
]
],
[
[
1647,
24,
1630
],
[
1630,
1,
673
]
],
[
[
1647,
21,
28792
],
[
28792,
60,
673
]
],
[
[
1647,
24,
1039
],
[
1039... | [
[
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aripiprazole"
]
],
[
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perphenazine"
],
[
... | Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Perphenazine and Perphenazine (Compound) resembles Aripiprazole (Compound)
Acarbose (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Aripiprazole (Compound)
Acarbose... |
DB00519 | DB06335 | 1,638 | 761 | [
"DDInter1843",
"DDInter1646"
] | Trandolapril | Saxagliptin | Trandolapril is a non-sulhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to its biologically active diacid form, trandolaprilat, in the liver. Trandolaprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiote... | Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. | Moderate | 1 | [
[
[
1638,
24,
761
]
],
[
[
1638,
21,
28966
],
[
28966,
60,
761
]
],
[
[
1638,
24,
104
],
[
104,
24,
761
]
],
[
[
1638,
24,
1296
],
[
1296,... | [
[
[
"Trandolapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Trandolapril",
"{u} (Compound) causes {v} (Side Effect)",
"Upper respiratory tract infection"
],
[
"Upper respirato... | Trandolapril (Compound) causes Upper respiratory tract infection (Side Effect) and Upper respiratory tract infection (Side Effect) is caused by Saxagliptin (Compound)
Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interacti... |
DB01036 | DB08899 | 211 | 129 | [
"DDInter1832",
"DDInter649"
] | Tolterodine | Enzalutamide | Tolterodine is an antimuscarinic drug that is used to treat urinary incontinence. Tolterodine acts on M2 and M3 subtypes of muscarinic receptors. | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
211,
24,
129
]
],
[
[
211,
24,
918
],
[
918,
1,
129
]
],
[
[
211,
6,
8374
],
[
8374,
45,
129
]
],
[
[
211,
21,
28921
],
[
28921,
... | [
[
[
"Tolterodine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Tolterodine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
],
... | Tolterodine may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide (Compound) resembles Enzalutamide (Compound)
Tolterodine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Tolterodine (Compound) causes Dizziness (Side Effect) an... |
DB00092 | DB00108 | 58 | 1,066 | [
"DDInter40",
"DDInter1268"
] | Alefacept | Natalizumab | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA re... | Major | 2 | [
[
[
58,
25,
1066
]
],
[
[
58,
23,
1114
],
[
1114,
62,
1066
]
],
[
[
58,
24,
949
],
[
949,
63,
1066
]
],
[
[
58,
24,
375
],
[
375,
64... | [
[
[
"Alefacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Natalizumab"
]
],
[
[
"Alefacept",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
],
[
"Zinc sulfat... | Alefacept may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Natalizumab
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani tox... |
DB01234 | DB06636 | 1,220 | 1,623 | [
"DDInter513",
"DDInter980"
] | Dexamethasone | Isavuconazonium | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Isavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA and July 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis, marketed by Astellas under the brand Cresemba. It is the prodrug form of isavuconazole, the active moiety, and it is... | Moderate | 1 | [
[
[
1220,
24,
1623
]
],
[
[
1220,
25,
466
],
[
466,
62,
1623
]
],
[
[
1220,
63,
1419
],
[
1419,
24,
1623
]
],
[
[
1220,
24,
309
],
[
309,
... | [
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isavuconazonium"
]
],
[
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Darolutamide"
],
[
... | Dexamethasone may lead to a major life threatening interaction when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Isavuconazonium
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib m... |
DB00431 | DB01227 | 1,503 | 1,301 | [
"DDInter1072",
"DDInter1043"
] | Lindane | Levacetylmethadol | An organochlorine insecticide that has been used as a pediculicide and a scabicide. Lindane has been banned in California, United Kingdom, Australia, and many western countries due to concerns about neurotoxicity and adverse effects on the environment. In Canada, Lindane is not recommmended as a first-line therapy due ... | Levacetylmethadol is a narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence. Levacetylmethadol was withdrawn from use in the European Union due to its high risk of QT interval prolongation. The production of levacetylmethadol in the US has ceased as well... | Moderate | 1 | [
[
[
1503,
24,
1301
]
],
[
[
1503,
24,
675
],
[
675,
1,
1301
]
],
[
[
1503,
63,
576
],
[
576,
1,
1301
]
],
[
[
1503,
63,
1648
],
[
1648,
... | [
[
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levacetylmethadol"
]
],
[
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextropropoxyphene"
],... | Lindane may cause a moderate interaction that could exacerbate diseases when taken with Dextropropoxyphene and Dextropropoxyphene (Compound) resembles Levacetylmethadol (Compound)
Lindane may cause a moderate interaction that could exacerbate diseases when taken with Methadone and Methadone (Compound) resembles Levacet... |
DB11130 | DB14575 | 407 | 733 | [
"DDInter1344",
"DDInter674"
] | Opium | Eslicarbazepine | Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papave... | Eslicarbazepine is an anti-epileptic medication available commercially as [eslicarbazepine acetate]. | Moderate | 1 | [
[
[
407,
24,
733
]
],
[
[
407,
63,
1264
],
[
1264,
24,
733
]
],
[
[
407,
24,
1609
],
[
1609,
24,
733
]
],
[
[
407,
63,
1264
],
[
1264,
... | [
[
[
"Opium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eslicarbazepine"
]
],
[
[
"Opium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Dox... | Opium may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Eslicarbazepine
Opium may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine and Pentoxyverine ... |
DB08901 | DB08913 | 1,468 | 1,186 | [
"DDInter1492",
"DDInter1561"
] | Ponatinib | Radium Ra 223 dichloride | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Radium Ra 223 Dichloride is a radiopharmaceutical containing the radioisotope radium-223 that emits short range but high linear energy alpha particles. As a cation, radium mimics calicum and binds to hydroxyapatite, which is a bone mineral found in areas of high bone turnover as seen in bone metastases. It was first ap... | Moderate | 1 | [
[
[
1468,
24,
1186
]
],
[
[
1468,
21,
28722
],
[
28722,
60,
1186
]
],
[
[
1468,
63,
134
],
[
134,
24,
1186
]
],
[
[
1468,
64,
1172
],
[
11... | [
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
]
],
[
[
"Ponatinib",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) i... | Ponatinib (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Radium Ra 223 dichloride (Compound)
Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with... |
DB00748 | DB01149 | 662 | 851 | [
"DDInter297",
"DDInter1274"
] | Carbinoxamine | Nefazodone | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the... | Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or ev... | Moderate | 1 | [
[
[
662,
24,
851
]
],
[
[
662,
63,
252
],
[
252,
40,
851
]
],
[
[
662,
24,
1178
],
[
1178,
1,
851
]
],
[
[
662,
24,
673
],
[
673,
40... | [
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nefazodone"
]
],
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxyzine"
],
... | Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyzine and Hydroxyzine (Compound) resembles Nefazodone (Compound)
Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Nefa... |
DB01118 | DB09073 | 33 | 951 | [
"DDInter76",
"DDInter1379"
] | Amiodarone | Palbociclib | Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation. Because of its ability to cause serious toxic... | Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery tha... | Moderate | 1 | [
[
[
33,
24,
951
]
],
[
[
33,
24,
1476
],
[
1476,
63,
951
]
],
[
[
33,
24,
259
],
[
259,
24,
951
]
],
[
[
33,
64,
467
],
[
467,
24,
... | [
[
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
]
],
[
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
... | Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilon... |
DB00549 | DB12010 | 522 | 214 | [
"DDInter1955",
"DDInter785"
] | Zafirlukast | Fostamatinib | Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), wh... | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
522,
24,
214
]
],
[
[
522,
24,
723
],
[
723,
24,
214
]
],
[
[
522,
24,
861
],
[
861,
63,
214
]
],
[
[
522,
63,
10
],
[
10,
24,
... | [
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
... | Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib and Ri... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.